Skip to main content

Table 4 Net reclassification improvements provided by LGE of the American and European risk strategies

From: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death

  LGE
≤ 10% 10.1–19.9% ≥ 20%
ACCF/AHA algorithm
 No events ICD not recommended 241 21 11
ICD can be useful 47 12 3
ICD reasonable 93 22 20
 Events ICD not recommended 2 4 2
ICD can be useful 2 1 3
ICD reasonable 2 3 4
Non-event NRI: 127/470 (0.27)
Event NRI: 2/23 (0.09)
Overall NRI: 0.36 (p = 0.021)
HCM Risk-SCD
 No events Low risk 298 32 21
Intermediate risk 44 12 3
High risk 39 11 10
 Events Low risk 2 5 4
Intermediate risk 1 2 4
High risk 3 1 1
Non-event NRI: 38/470 (0.08)
Event NRI: 8/23 (0.35)
Overall NRI: 0.43 (p = 0.011)
  1. ACCF/AHA American College of Cardiology Foundation / American Heart Association, HCM Risk-SCD hypertrophic cardiomyopathy risk sudden cardiac death, ICD implantable cardioverter defibrillator, LGE late gadolinium enhancement, NRI net reclassification index